MTNB Prakiraan wutah bathi kanggo taun ngarep matinasbiopharma.com
Matinas BioPharma (MTNB) management is demonstrating transparency in the LNC system and MAT2203 trials while effectively protecting intellectual property. The valuation of expected EPS growth for the coming year confirms market optimism, where the 0.00 level serves as the current metric. Matinas BioPharma (MTNB) is diversifying its anti-inflammatory developments by implementing oral administration. These R&D solutions enable the replacement of injections with convenient tablets, expanding access to mass markets.
MTNB (Matinas BioPharma Holdings): rincian analitis lan laporan miturut indikator
- rega saham lan konsensus proyeksi valuasi:
- data kapitalisasi pasar:
- indikator kapitalisasi buku:
- informasi babagan utang lan solvabilitas:
Total Utang marang Modal Matinas BioPharma|MTNB - Rasio tanggungan utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas Matinas BioPharma Holdings, Inc.|MTNB - Gunggung kewajiban utang perusahaan|Rasio utang marang kapitalisasi buku Matinas BioPharma|MTNB - Kewajiban jangka dawa perusahaan|Utang jangka cendhak perusahaan Matinas BioPharma|Rasio cepet matinasbiopharma.com
- data bathi resik lan rasio valuasi:
MTNB - Bathi resik|Bathi mangsa ngarep Matinas BioPharma|MTNB - Rasio rega pasar marang bathi resik|Pangali Forward P/E Matinas BioPharma Holdings, Inc.|MTNB - Kapitalisasi marang bathi resik kanthi nimbang wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Matinas BioPharma|MTNB - Bathi operasional sadurunge amortisasi|Bathi resik saben saham (EPS TTM) Matinas BioPharma|MTNB - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan matinasbiopharma.com|MTNB - Prakiraan wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi saben saham kanggo taun ngarep Matinas BioPharma
- data total pendapatan lan volume dodolan:
Analisis wiwitan perusahaan:MTNB, Matinas BioPharma
This indicator measures the consensus earnings per share (EPS) forecast, reflecting the balance between institutional expectations and the business's actual ability to absorb costs. The current value of 0.00 allows for an assessment of asset overvaluation risk, while the projected EPS growth rate for next year depends directly on the expansion of the licensee pool and the success of Matinas BioPharma (MTNB) joint developments in the complex molecule delivery segment.
Analisis perusahaan pesaing
ASND (Ascendis Pharma Inc.) - Prakiraan wutah bathi kanggo taun ngarep|Prakiraan wutah bathi kanggo taun ngarep Madrigal Corp|Prakiraan wutah bathi kanggo taun ngarep CORT|Prakiraan wutah bathi resik saben saham kanggo taun ngarep RYTM (rhythmtx.com)|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Akero AKRO|Metsera, Inc. (MTSR) - Prakiraan wutah bathi resik saben saham ing taun ngarep|MLTX - Prakiraan wutah bathi resik saben saham kanggo taun ngarep|CRNX: Prakiraan wutah bathi resik saben saham kanggo taun ngarep|NAMS: Prakiraan wutah bathi kanggo taun ngarep|SLNO - Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Amicus Therapeutics, Inc.|89bio Inc (ETNB) - Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Agios Pharmaceuticals Inc (AGIO)|Prakiraan wutah bathi saben saham kanggo taun ngarep Structure Corp GPCR|Prakiraan wutah bathi resik saben saham kanggo taun ngarep MiMedx Group, Inc. MDXG|RZLT - Prakiraan wutah bathi saben saham kanggo taun ngarep|Lexicon Pharmaceuticals, Inc. - Prakiraan wutah bathi kanggo taun ngarep|MBX - Prakiraan wutah bathi kanggo taun ngarep|ALT (Altimmune Corp) - Prakiraan wutah bathi saben saham kanggo taun ngarep|AARD: Proyeksi tambahing bathi saben saham ing taun ngarep|SGMT (Sagimet Biosciences) - Prakiraan wutah bathi kanggo taun ngarep|bioagelabs.com (BIOA) - Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Biomea Fusion (BMEA)|quincetx.com - Proyeksi kacepetan wutah bathi saben saham kanggo taun ngarep|Prakiraan wutah bathi kanggo taun ngarep GUTS (Fractyl)|Prakiraan wutah bathi kanggo taun ngarep vTv Therapeutics, Inc. VTVT|ATPC - Prakiraan wutah bathi resik saben saham kanggo taun ngarep|Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep Pluri Inc. PLUR|SYBX (synlogictx.com) - Prakiraan wutah bathi saben saham kanggo taun ngarep|Lipocine Inc - Dinamika bathi saben saham sing diarepake ing taun ngarep|SPRB (Spruce Biosciences, Inc.) - Prakiraan wutah bathi kanggo taun ngarep|Prakiraan wutah bathi resik saben saham kanggo taun ngarep GLTO|Prakiraan wutah bathi kanggo taun ngarep CTCX|Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep lumos-pharma.com|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Organovo ONVO|Radius Recycling Inc. (RDUS) - Prakiraan wutah bathi resik saben saham ing taun ngarep
